Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Grifols Sa and Aradigm Corp (NASDAQ:ARDM)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Grifols, S.A 5,244,363 3,829,175 5,244,363 3,829,175 9,073,538 48.3%
Grifols Worldwide Operations Limited 0 3,829,175 0 3,829,175 3,829,175 20.4%

Page 1 of 12 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

(Amendment No. 1)

Under the Securities Exchange Act of 1934*

 

 

ARADIGM
CORPORATION

(Name of Issuer)

 

 

Common Stock,
no par value

(Title of Class of Securities)

038505400

(CUSIP Number)

Grifols, S.A.

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Valles 08174, Barcelona, Spain

Tel: +34 93 571 0500

Attention: David Bell

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

with a copy to:

Proskauer Rose LLP Osborne Clarke S.L.P.
Eleven Times Square Avenida Diagonal, 477
New York, NY 10036 Planta 20, 08036 Barcelona, Spain
Tel: (212) 969-3000 Tel: +34 93 419 1818
Attention: Peter G. Samuels, Esq. Attention: Tomás Dagá

April 21, 2016

(Date of Event Which Requires Filing of this Statement)

 

 

If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other
parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be
deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).

Follow Aradigm Corp (NASDAQ:ARDM)
Trade (NASDAQ:ARDM) Now!

Page 2 of 12 – SEC Filing


CUSIP No. 038505400 SCHEDULE 13D Page
2
of 12
  1

NAMES OF
REPORTING PERSONS

Grifols, S.A.

  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP (SEE INSTRUCTIONS)

(a)  ☐        (b)  ☒

  3

SEC USE ONLY

  4

SOURCE OF FUNDS (SEE INSTRUCTIONS)

WC, AF

  5

CHECK IF DISCLOSURE OF LEGAL
PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

  6

CITIZENSHIP OR PLACE OF
ORGANIZATION

Spain

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

  7

SOLE VOTING POWER

5,244,363

  8

SHARED VOTING POWER

3,829,175

  9

SOLE DISPOSITIVE POWER

5,244,363

10

SHARED DISPOSITIVE POWER

3,829,175

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9,073,538

12

CHECK IF THE AGGREGATE AMOUNT IN ROW
(11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

13

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (11)

48.3%

14

TYPE OF REPORTING PERSON (SEE
INSTRUCTIONS)

CO

2

Follow Aradigm Corp (NASDAQ:ARDM)
Trade (NASDAQ:ARDM) Now!

Page 3 of 12 – SEC Filing


CUSIP No. 038505400 SCHEDULE 13D Page
3
of 12
  1

NAMES OF
REPORTING PERSONS

Grifols Worldwide Operations Limited

  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP (SEE INSTRUCTIONS)

(a)  ☐        (b)  ☒

  3

SEC USE ONLY

  4

SOURCE OF FUNDS (SEE INSTRUCTIONS)

WC

  5

CHECK IF DISCLOSURE OF LEGAL
PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

  6

CITIZENSHIP OR PLACE OF
ORGANIZATION

Ireland

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

  7

SOLE VOTING POWER

0

  8

SHARED VOTING POWER

3,829,175

  9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

3,829,175

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,829,175

12

CHECK IF THE AGGREGATE AMOUNT IN ROW
(11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

13

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (11)

20.4%

14

TYPE OF REPORTING PERSON (SEE
INSTRUCTIONS)

CO

3

Follow Aradigm Corp (NASDAQ:ARDM)
Trade (NASDAQ:ARDM) Now!

Page 4 of 12 – SEC Filing


CUSIP No. 038505400 SCHEDULE 13D Page 4 of 12

Item 2. Identity and Background

Item 2 of this Schedule 13D is amended and restated as follows:

(a) through (c), (f)

This
Schedule 13D is being filed by Grifols, S.A., a company organized under the laws of Spain (Grifols), and Grifols Worldwide Operations Limited, a company organized under the laws of Ireland and a wholly-owned subsidiary of Grifols
(Grifols Worldwide and, together with Grifols, the Reporting Persons). The address of the principal office of Grifols is Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles
08174, Barcelona, Spain, and of Grifols Worldwide is Grange Castle Business Park, Grange Castle, Clondalkin, Dublin 22, Ireland. Grifols is a global healthcare company and leading producer of plasma protein therapies. Grifols researches, develops,
manufactures and markets plasma derivatives, IV therapy, enteral nutrition, diagnostic systems and medical materials. Grifols Worldwide is engaged in the packaging, labeling, storage, distribution, manufacture and development of pharmaceutical
products and the rendering of financial services to Grifols and its owned or controlled companies.

Attached as Schedule A hereto,
and incorporated by reference herein, is a chart setting forth the name, business address, present principal occupation or employment (along with the name, principal business and address of any corporation or other organization in which such
employment is conducted) and citizenship of each director and executive officer of each of Grifols and Grifols Worldwide (collectively, the Schedule A Persons).

(d) and (e)

During the last five
years, neither Grifols, Grifols Worldwide nor to the knowledge of Grifols and Grifols Worldwide, any of the Schedule A Persons has (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or
(ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount
of Funds or Other Consideration

Item 3 of this Schedule 13D is amended and supplemented as follows:

On April 26, 2016, pursuant to the Convertible Notes Purchase Agreement (as defined in Item 4), Grifols Worldwide purchased
$19,950,000 aggregate principal amount of 9% senior convertible notes due 2021 issued by the Issuer for cash consideration of $19,950,000. Grifols Worldwide used its cash on hand to make such payment.

The information set forth in Item 4 of this Amendment No. 1 to the Schedule 13D is incorporated in this Item 3 by reference.

Item 4. Purpose of Transaction

Item 4 of
this Schedule 13D is amended and supplemented to add the disclosure under (and including) the heading Convertible Notes Purchase Agreement and Indenture. The disclosure under the heading Governance Agreement in Item 4 of
this Schedule 13D is amended and supplemented to add the disclosure under the heading Amendment to Governance Agreement.

4

Follow Aradigm Corp (NASDAQ:ARDM)
Trade (NASDAQ:ARDM) Now!

Page 5 of 12 – SEC Filing


CUSIP No. 038505400 SCHEDULE 13D Page 5 of 12

Convertible Notes Purchase Agreement and Indenture

On April 21, 2016, the Issuer entered into a Securities Purchase Agreement (the Convertible Notes Purchase Agreement)
with Grifols Worldwide and other purchasers identified therein whereby Grifols Worldwide agreed to purchase $19,950,000 aggregate principal amount of 9% senior convertible notes due 2021 (the Notes) issued by the Issuer. Grifols
Worldwide consummated its purchase of the Notes on April 26, 2016. The Notes were issued pursuant to an Indenture dated April 25, 2016 (the Indenture) between the Issuer and U.S. Bank National Association, as trustee.
The Notes bear interest at a rate of 9% per annum, payable semi-annually (on May 1 and November 1) in arrears, unless earlier purchased or converted. The Notes mature on May 1, 2021 (the Maturity Date). The
Notes are convertible at the option of Grifols Worldwide at any time prior to the close of business on the second business day immediately preceding the Maturity Date. The initial conversion rate of the Notes is 191.9386 shares of common stock for
each $1,000 principal amount of Notes, which represents an initial conversion price of approximately $5.21 per share of common stock. The conversion rate of the Notes, and the corresponding conversion price, will be subject to adjustment for certain
events. At the current conversion rate, the Notes are convertible into 3,829,175 Shares.

Grifols Worldwide acquired the Notes for
investment purposes. The Reporting Persons may, from time to time, and subject to Governance Agreement (as it may be amended, supplemented, or waived, from time to time), depending upon market conditions and other investment considerations, purchase
additional securities of the Issuer for investment or dispose of currently owned Shares or the Notes or engage in any other actions contemplated in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

The foregoing description of the Convertible Notes Purchase Agreement is qualified in its entirety by reference to the full text of the
Convertible Notes Purchase Agreement, which is filed as Exhibit 13 and is incorporated herein by reference. The foregoing description of the Notes and the Indenture is qualified in its entirety by reference to the full text of the Indenture,
which is filed as Exhibit 14 and is incorporated herein by reference.

Amendment to Governance Agreement

In connection with Grifols Worldwides purchase the Notes, Grifols and the Issuer entered into an amendment of the Governance Agreement,
dated April 21, 2016, pursuant to which the Target Percentage was increased to 43.3% (the Governance Agreement Amendment). Additionally, Grifols and the Issuer also entered into waivers pursuant to which Grifols waived
certain registration and preemptive rights under the Governance Agreement.

The foregoing description of the Governance Agreement
Amendment is qualified in its entirety by reference to the full text of the Governance Agreement Amendment, which is filed as Exhibit 15 and is incorporated herein by reference.

Item 5. Interest in Securities of the Issuer

Item 5 of this Schedule 13D is amended and restated as follows:

(a) and (b)

The information set
forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 14,951,089 outstanding Shares as of March 12, 2017, as reported in the Issuers Form 10-K filed
on March 30, 2017. Grifols owns 100% of the equity interests of Grifols Worldwide and may be deemed to beneficially own Shares that are beneficially owned by Grifols Worldwide.

Ramón Riera Roca (Riera), Chief Operations Officer and a member of the Board of Directors of Grifols, directly
beneficially owns 12,500 Shares. Riera has the sole power to vote or direct the voting of, and the sole power to dispose or to direct the disposition of, such Shares. Such Shares represent less than 0.1% of all Shares outstanding.

Except as set forth in this Item 5(a), to the knowledge of Grifols and Grifols Worldwide, none of the Schedule A Persons beneficially
owns any Shares.

5

Follow Aradigm Corp (NASDAQ:ARDM)
Trade (NASDAQ:ARDM) Now!

Page 6 of 12 – SEC Filing


CUSIP No. 038505400 SCHEDULE 13D Page 6 of 12

(c)

Except as described under Convertible Notes Purchase Agreement and Indenture under Item 4, no transactions in the Shares have
been effected by Grifols or Grifols Worldwide, and to the knowledge of Grifols and Grifols Worldwide, by any Schedule A Persons, since the initial filing of this Schedule 13D.

(d)

No person (other than
Grifols or Grifols Worldwide) has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares disclosed as beneficially owned by this Schedule 13D.

(e)

Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6 of this Schedule 13D is amended and supplemented as follows:

The information set forth in Items 3, 4 and 5 of this Amendment No. 1 to the Schedule 13D is incorporated in this Item 6 by
reference. Other than as described in this Amendment No. 1 to the Schedule 13D and the agreements incorporated by reference herein and set forth as exhibits hereto, Grifols and Grifols Worldwide do not have, and, to the knowledge of Grifols and
Grifols Worldwide, the Schedule A Persons do not have, any contract, arrangement, understanding or relationship (legal or otherwise) with any other person with respect to any securities of the Issuer.

Item 7. Material to Be Filed as Exhibits

Item 7 of this Schedule 13D is amended and supplemented as follows:

Exhibit 12 Joint Filing Agreement.
Exhibit 13 Securities Purchase Agreement, dated as of April 21, 2016, by and between Aradigm Corporation and the Purchasers Named on Schedules A and B thereto (incorporated by reference to Exhibit 10.1 to the Issuers Form 8-K/A filed on
April 28, 2016).
Exhibit 14 Indenture, dated as of April 25, 2016, between Aradigm Corporation and U.S. Bank National Association, as Trustee (incorporated by reference to Exhibit 10.2 to the Issuers Form 8-K/A filed on April 28, 2016).
Exhibit 15 Amendment to Governance Agreement, dated as of April 21, 2016, by and between Aradigm Corporation and Grifols, S.A. (incorporated by reference to Exhibit 10.6 to the Issuers Form 8-K/A filed on April 28, 2016).

6

Follow Aradigm Corp (NASDAQ:ARDM)
Trade (NASDAQ:ARDM) Now!

Page 7 of 12 – SEC Filing


CUSIP No. 038505400 SCHEDULE 13D Page 7 of 12

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.

Date: April 4, 2017

GRIFOLS, S.A.
By:

/s/ David I. Bell

Name: David I. Bell
Title: Authorized Signatory
GRIFOLS WORLDWIDE OPERATIONS LIMITED
By:

/s/ Alfredo Arroyo

Name: Alfredo Arroyo
Title: Authorized Signatory

7

Follow Aradigm Corp (NASDAQ:ARDM)
Trade (NASDAQ:ARDM) Now!

Page 8 of 12 – SEC Filing


CUSIP No. 038505400 SCHEDULE 13D Page
8
of 12

Schedule A

Directors and Executive Officers of Grifols

The following tables set forth the name, present principal occupation or employment (along with the name, principal business and address of
any corporation or other organization in which such employment is conducted) and citizenship of each director and executive officer of Grifols.

Board of Directors

Name of Director

Country of

Citizenship

Principal Occupation or

Employment

Name, Address and Principal

Business of Employer

Víctor Grifols Roura Spain Non-executive Chairman of the Board of Directors of Grifols, S.A.

Grifols S.A.

Parc Empresarial Can Sant
Joan,
Avinguda de la Generalitat, 152

08174 Sant Cugat del Valles,

Barcelona, Spain

Raimon Grifols Roura Spain Chief Executive Officer and Member of the Board of Directors of Grifols, S.A.

Grifols S.A.

Parc Empresarial Can Sant
Joan,
Avinguda de la Generalitat, 152
08174 Sant Cugat del Valles,

Barcelona, Spain

Victor Grifols Deu Spain Chief Executive Officer and Member of the Board of Directors of Grifols, S.A.

Grifols S.A.

Parc Empresarial Can Sant
Joan,

Avinguda de la Generalitat, 152

08174 Sant
Cugat del Valles,

Barcelona, Spain

Ramón Riera Roca Spain Chief Operations Officer and Member of the Board of Directors of Grifols, S.A.

Grifols S.A.

Parc Empresarial Can Sant
Joan,
Avinguda de la Generalitat, 152

08174 Sant Cugat del Valles,

Barcelona, Spain

Tomás Dagá Gelabert Spain Senior Partner at the law firm of Osborne Clark S.L.P.

Osborne Clarke S.L.P

Avenida Diagonal 477

08036, Barcelona, Spain

Thomas H. Glanzmann Switzerland Member of the Board of Directors of Grifols, S.A.

Glanzmann Enterprises

Opfikonerstrasse 10,
8303

Bassersdorf, Switzerland

Anna Veiga Lluch Spain Director, Barcelona Stem Cell

Stem Cell Bank, Centre for Regenerative Medicine in

Barcelona

Dr. Aiguader, 88

08003 Barcelona, Spain

8

Follow Aradigm Corp (NASDAQ:ARDM)
Trade (NASDAQ:ARDM) Now!

Page 9 of 12 – SEC Filing


CUSIP No. 038505400 SCHEDULE 13D Page
9
of 12
Steven Francis Mayer United States Senior Managing Director and Co-Head of Private Equity at Cerberus Capital Management, L.P.

Cerberus California, LLC

11812 San Vencente
Blvd

Suite 300

Los Angeles, CA 90049

Luís Isasi Fernández de Bobadilla Spain Managing Director, Morgan Stanley

Morgan Stanley S.V. S.A.

Serrano, 55

28006 Madrid, Spain

Belén Villalonga Morenés Spain Associate Professor

New York University Stern School of Business

Tisch 721

40 West
4th St

New York, NY 10012

Marla E. Salmon United States Professor of Nursing and Public Health

University of Washington

Evans School of Public
Affairs

Box 357663

Seattle, WA 98195

Iñigo Sánchez-Asiaín Mardones Spain Member of the Executive Committee and Investment Committee, Portobello Capital

Portobello Capital

Almagro 36, 2°
planta

28010 Madrid, Spain

Carina Szpilka Lázaro Spain Vice-President, UNICEF

Rafael Calvo 40, 1º2ª

28010 Madrid,
Spain

Executive Officers

(other than Members of the Board of Directors)

Name of

Executive Officer

Country of
Citizenship

Title

Name, Address and Principal

Business of Employer

Alfredo Arroyo Guerra Spain Corporate Vice President and Chief Financial Officer Embassy House, Ballsbridge, Dublin 4, Ireland
Carlos Roura Fernández Spain Chief Industrial Officer

Grifols, S.A.

Parc Empresarial Can Sant
Joan,

Avinguda de la Generalitat, 152

08174 Sant Cugat del
Valles,

Barcelona, Spain

Montserrat Lloveras Calvo Spain Corporate Vice President and Director of Corporate Accounting and Reporting

Grifols S.A.

Parc Empresarial Can Sant
Joan,

Avinguda de la Generalitat, 152

08174 Sant Cugat del
Valles,

Barcelona, Spain

9

Follow Aradigm Corp (NASDAQ:ARDM)
Trade (NASDAQ:ARDM) Now!

Page 10 of 12 – SEC Filing


CUSIP No. 038505400 SCHEDULE 13D Page
10
of 12
Vicente Blanquer Torre Spain Corporate Vice President, Quality & R&D

Grifols S.A.

Parc Empresarial Can Sant
Joan,

Avinguda de la Generalitat, 152

08174 Sant Cugat del
Valles,

Barcelona, Spain

Mateo Florencio

Borras Humbert

Spain Corporate Vice President and Director of Global Human Resources

Grifols S.A.

Parc Empresarial Can Sant
Joan,

Avinguda de la Generalitat, 152

08174 Sant Cugat del
Valles,

Barcelona, Spain

Francisco Javier Jorba Ribes Spain Corporate Vice President and President of Biological Industrial Group

Grifols S.A.

Parc Empresarial Can Sant
Joan,

Avinguda de la Generalitat, 152

08174 Sant Cugat del
Valles,

Barcelona, Spain

Gregory Gene Rich United States Corporate Vice President and President and Chief Executive Officer of Grifols Shared Services North America, Inc.

Grifols Inc.

2410 Lillyvale Avenue

Los Angeles, CA 90032

David Ian Bell United States and United Kingdom Chief Innovation Officer and General Counsel Grifols, S.A.; President of GIANT Ltd.

Grange Castle Business Park

Grange Castle,
Clondalikn,

Dublin 22, Ireland

Nuria Pascual Lapeña Spain Corporate Vice President, Treasury, Risk Management and IRO

Grifols S.A.

Parc Empresarial Can Sant
Joan,

Avinguda de la Generalitat, 152

08174 Sant Cugat del
Valles,

Barcelona, Spain

Shinji Wada United States Corporate Vice President and President of Plasma Operations of Grifols Shared Services North America, Inc.

Grifols S.A.

2410 Lillyvale Avenue

Los Angeles, CA 90032

Lafmin Morgan United States President of the Bioscience and Hospital Division

Grifols S.A.

79 TW Alexander Dr Bldg 4101

Raleigh, NC 27709

Carsten Schroeder Germany President of the Diagnostic Division

Grifols S.A.

4560 Horton Street

Emeryville, CA 94608

Juan Ignacio

Twose Roura

Spain Member of the Advisory Committee

Grifols S.A.

Parc Empresarial Can Sant
Joan,

Avinguda de la Generalitat, 152

08174 Sant Cugat del
Valles,

Barcelona, Spain

10

Follow Aradigm Corp (NASDAQ:ARDM)
Trade (NASDAQ:ARDM) Now!

Page 11 of 12 – SEC Filing


CUSIP No. 038505400 SCHEDULE 13D Page
11
of 12

Directors and Executive Officers of Grifols Worldwide

The following tables set forth the name, present principal occupation or employment (along with the name, principal business and address of
any corporation or other organization in which such employment is conducted) and citizenship of each director and executive officer of Grifols Worldwide.

Board of Directors

Name of Director

Country of
Citizenship

Principal Occupation or Employment

Name, Address and Principal Business of Employer

Tomás Dagá Gelabert Spain Senior Partner at the law firm of Osborne Clark S.L.P.

Avenida Diagonal 477

08036, Barcelona,
Spain

Alfredo Arroyo Guerra Spain Corporate Vice President and Chief Financial Officer of Grifols, S.A.

Embassy House, Ballsbridge,

Dublin 4,
Ireland

Ramón Riera Roca Spain Chief Operations Officer and Member of the Board of Directors of Grifols, S.A.

Grifols S.A.

Parc Empresarial Can Sant
Joan,

Avinguda de la Generalitat, 152

08174 Sant Cugat del
Valles,

Barcelona, Spain

Eduardo Herrero Spain Deputy President, Bioscience

Grifols S.A.

Parc Empresarial Can Sant
Joan,

Avinguda de la Generalitat, 152

08174 Sant Cugat del
Valles,

Barcelona, Spain

Vicente Blanquer Torre Spain Corporate Vice President, Quality & R&D of Grifols, S.A.

Grifols S.A.

Parc Empresarial Can Sant
Joan,

Avinguda de la Generalitat, 152

08174 Sant Cugat del
Valles,

Barcelona, Spain

Jordi Casas Spain Director, Osborne Clark S.L.P.

Avenida Diagonal 477

08036, Barcelona,
Spain

Alfred Grifols Coma-Cros Ireland Managing Director

Grange Castle Business Park

Grange Castle,
Clondalikn,

Dublin 22, Ireland

11

Follow Aradigm Corp (NASDAQ:ARDM)
Trade (NASDAQ:ARDM) Now!

Page 12 of 12 – SEC Filing


CUSIP No. 038505400 SCHEDULE 13D Page
12
of 12

Executive Officers

(other than Members of the Board of Directors)

Name of Executive Officer

Country of Citizenship

Title

Name, Address and Principal Business

of Employer

Lafmin Morgan United States President, Bioscience Division

Grifols Inc.

79 T.W. Alexander Drive |
4101

Research Commons | Research

Triangle Park, NC
27709

Ann OConnor Ireland Technical Director

Grange Castle Business Park, Grange

Castle,
Clondalkin, Dublin 22, Ireland

Siobhan Lynch Ireland HR Business Partner

Grange Castle Business Park, Grange

Castle,
Clondalkin, Dublin 22, Ireland

Terry Ginsberg Ireland Senior Advisor, Global Tax & Risk Management

Grange Castle Business Park, Grange

Castle,
Clondalkin, Dublin 22, Ireland

Albert Grifols Spain Deputy Chief Industrial Officer

Avda. de la Generalitat,152-158

08174 Sant
Cugat del Vallés-Barcelona-Spain

Jaume Carreras Ireland VP, Global Logistics & Services Grange Castle Business Park, Grange Castle, Clondalkin, Dublin 22, Ireland
Wendy Fong Ireland VP, Global Supply Planning Grange Castle Business Park, Grange Castle, Clondalkin, Dublin 22, Ireland
Carlos Roura Spain VP, Chief Industrial Officer

Avda. de la Generalitat,152-158

08174 Sant
Cugat del Vallés-Barcelona-Spain

12

Follow Aradigm Corp (NASDAQ:ARDM)
Trade (NASDAQ:ARDM) Now!